Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

DISEASE CHARACTERISTICS:

Histologically or cytologically proven advanced malignancy that is refractory to prior therapy or unlikely to benefit from standard therapy (e.g., chemotherapy, radiotherapy, and surgery)

Part I: Previously untreated OR minimally pretreated

Ineligible for part I and considered heavily pretreated if:

Prior radiotherapy to wide ports involving the pelvis or at least 25% of bone marrow
Greater than 6 courses of prior combination chemotherapy including alkylating agent
Prior nitrosoureas or mitomycin
Widespread bone metastases with bone marrow involvement by bone marrow biopsy (positive bilateral bone marrow biopsy for lymphoma patients)
Part II: Heavily pretreated as defined above
Measurable or evaluable disease

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

SWOG 0-2

Life expectancy:

At least 3 months

Hematopoietic:

Absolute neutrophil count greater than 1,500/mm^3
Hemoglobin greater than 9 mg/dL
Platelet count greater than 100,000/mm^3

Hepatic:

Bilirubin less than 1.5 mg/dL

Renal:

Creatinine less than 1.5 mg/dL

Cardiovascular:

No uncontrolled hypertension
No angina pectoris
No clinically significant, multifocal, uncontrolled cardiac dysrhythmias

Other:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No active serious infection
No clinically severe peripheral neuropathy (grade 1 or worse)
No nonmalignant medical condition that would preclude compliance or increase risk of participation in study
No hypersensitivity to E. coli derived drug preparations

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No other concurrent colony stimulating factors for prophylactic purposes

Chemotherapy:

At least 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas and mitomycin) and recovered

Endocrine therapy:

No chronic oral corticosteroids
No concurrent corticosteroids except as prophylactic antiemetic

Radiotherapy:

At least 3 weeks since prior radiotherapy and recovered

Other:

At least 1 month since prior investigational agent
No prophylactic oral or IV antibiotics for neutropenia unless fever present
No other concurrent anticancer treatment or investigational agent